Loading stock data…
CHF 584.60+18.20 (+3.21%)
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.
Lonza Group AG in the Healthcare sector is trading at $584.60 with a market capitalization of $39.3B. Wall Street consensus targets $689.48 (23 analysts), implying a +17.9% move over the next 12 months. The stock is currently near its 52-week high of $597.80, remaining 10.2% above its 200-day moving average. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (CHF) · Annual | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Total Revenue | CHF 6.22B↓ | CHF 6.72B↑ | CHF 5.48B↓ | CHF 6.53B |
| Gross Profit | CHF 2.44B↑ | CHF 1.95B↑ | CHF 1.79B↓ | CHF 2.31B |
| Operating Income | CHF 1.36B↑ | CHF 873.00M↓ | CHF 879.00M↓ | CHF 1.36B |
| Net Income | CHF 1.22B↑ | CHF 654.00M↑ | CHF 636.00M↑ | -CHF 275.00M |
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally....